- $368.55m
- $326.71m
- $79.18m
Brief: Simulations Plus And The University Of Connecticut Receive New FDA Grant To Expand Mechanistic Modeling Approaches For Long-Acting Injectables
Simulations Plus Inc reports results for the quarter ended in August 31 - Earnings Summary
Brief: Simulations Plus Q4 Revenue USD 18.7 Million Vs. IBES Estimate USD 19.7 Million
Simulations Plus Inc expected to post earnings of 3 cents a share - Earnings Preview
Brief: Simulations Plus Optimizes Business Unit Structure
Simulations Plus Inc reports results for the quarter ended in May - Earnings Summary
Brief: Simulations Plus Q3 Revenue USD 18.5 Million Vs. IBES Estimate USD 17.9 Million
Simulations Plus Inc expected to post earnings of 15 cents a share - Earnings Preview
Brief: QHP Capital-Backed Pro-Ficiency Acquired By Simulations Plus
Brief: Simulations Plus Acquires Pro-Ficiency, Creating One-Of-A-Kind Platform Spanning The Drug Development Continuum
Simulations Plus Inc reports results for the quarter ended in February - Earnings Summary
Brief: Simulations Plus Q2 Revenue USD 18.3 Million
Simulations Plus Inc expected to post earnings of 19 cents a share - Earnings Preview
Simulations Plus Inc reports results for the quarter ended in November - Earnings Summary
Brief: Simulations Plus Reports First Quarter Fiscal 2024 Financial Results
Brief: Simulations Plus Q1 Revenue USD 14.5 Million
Simulations Plus Inc expected to post earnings of 10 cents a share - Earnings Preview
Brief: Simulations Plus Announces First Quarter Fiscal Year 2024 Earnings And Conference Call Date
Simulations Plus Inc reports results for the quarter ended in August - Earnings Summary